CN: 32-1845/R
ISSN: 2095-6975
Cite this paper:
WU Gao-Song, LI Hou-Kai, ZHANG Wei-Dong. Metabolomics and its application in the treatment of coronary heart disease with traditional Chinese medicine[J]. Chinese Journal of Natural Medicines, 2019, 17(5): 321-330

Metabolomics and its application in the treatment of coronary heart disease with traditional Chinese medicine

WU Gao-Song1, LI Hou-Kai1, ZHANG Wei-Dong1,2
1 Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China;
2 School of Pharmacy, Second Military Medical University, Shanghai 200433, China
Traditional Chinese Medicine (TCM) is the treasure of Chinese Nation and gained the gradual acceptance of the international community. However, the methods and theories of TCM understanding of diseases are lack of appropriate modern scientific characterization systems. Moreover, traditional risk factors cannot promote to detection and prevent those patients with coronary artery disease (CAD) who have not developed acute myocardial infarction (MI) in time. To sum up, there is still no objective systematic evaluation system for the therapeutic mechanism of TCM in the prevention and cure of cardiovascular disease. Thus, new ideas and technologies are needed. The development of omics technology, especially metabolomics, can be used to predict the level of metabolites in vivo and diagnose the physiological state of the body in time to guide the corresponding intervention. In particular, metabolomics is also a very powerful tool to promote the modernization of TCM and the development of TCM in personalized medicine. This article summarized the application of metabolomics in the early diagnosis, the discovery of biomarkers and the treatment of TCM in CAD.
Key words:    Traditional Chinese medicine    Metabolomics    Coronary heart disease    Biomarkers    Research progress   
Received: 2019-01-23   Revised:
PDF (1583 KB) Free
Print this page
Email this article to others
Articles by WU Gao-Song
Articles by LI Hou-Kai
Articles by ZHANG Wei-Dong
[1] Pagidipati NJ, Gaziano TA. Estimating deaths from cardio-vascular disease:a review of global methodologies of mortality measurement[J]. Circulation, 2013, 127(6):749-756.
[2] Yang ZJ, Liu J, Ge JP, et al. Prevalence of cardiovascular disease risk factor in the Chinese population:the 2007-2008 China National Diabetes and Metabolic Disorders Study[J]. Eur Heart J, 2012, 33(2):213-220.
[3] Khor GL. Cardiovascular epidemiology in the Asia-Pacific region[J]. Asia Pac J Clin Nutr, 2001, 10(2):76-80.
[4] Steinberg D, Witztum JL. Oxidized low-density lipoprotein and atherosclerosis[J]. Arterioscler Thromb Vasc Biol, 2010, 30(12):2311-2316.
[5] Writing Group M, Mozaffarian D, Benjamin EJ, et al. Executive summary:Heart disease and stroke statistics-2016 Update:A report from the American Heart Association[J]. Circulation, 2016, 133(4):447-454.
[6] Meikle PJ, Wong G, Barlow CK, et al. Lipidomics:potential role in risk prediction and therapeutic monitoring for diabetes and cardiovascular disease[J]. Pharmacol Ther, 2014, 143(1):12-23.
[7] Anderson JL, Adams CD, Antman EM, et al. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. Circulation, 2011, 123(18):e426-579.
[8] Hoefer IE, Steffens S, Ala-Korpela M, et al. Novel methodologies for biomarker discovery in atherosclerosis[J]. Eur Heart J, 2015, 36(39):2635-2642.
[9] Gerszten RE, Wang TJ. The search for new cardiovascular biomarkers[J]. Nature, 2008, 451(7181):949-952.
[10] Rhee EP, Gerszten RE. Metabolomics and cardiovascular biomarker discovery[J]. Clin Chem, 2012, 58(1):139-147.
[11] Sun H, Zhang A, Wang X. Potential role of metabolomic approaches for Chinese medicine syndromes and herbal medicine[J]. Phytother Res, 2012, 26(10):1466-1471.
[12] Wang X, Sun H, Zhang A, et al. Potential role of metabolomics apporoaches in the area of traditional Chinese medicine:as pillars of the bridge between Chinese and Western medicine[J]. J Pharm Biomed Anal, 2011, 55(5):859-868.
[13] Lu XY, Xu H, Li G, et al. Study on correspondence between prescription and syndrome and the essence of phlegm and blood stasis syndrome in coronary heart disease based on metabonomics[J]. Chin J Integr Med, 2014, 20(1):68-71.
[14] Qiu Q, Li C, Wang Y, et al. Plasma metabonomics study on Chinese medicine syndrome evolution of heart failure rats caused by LAD ligation[J]. BMC Complement Altern Med, 2014, 14:232.
[15] Cheng P, Chen ZQ, Wang DS. Metabonomics research on coronary heart disease patients of phlegm turbidity syndrome and qi deficiency syndrome[J]. Chin J Integr Tradit West Med, 2015, 35(2):193-197.
[16] Lu XY, Xu H, Zhao T, et al. Study of serum metabonomics and formula-pattern correspondence in coronary heart disease patients diagnosed as phlegm or blood stasis pattern based on ultra performance liquid chromatography mass spectrometry[J]. Chin J Integr Med, 2018, 24(12):905-911.
[17] Wang Y, Li C, Chang H, et al. Metabolomic profiling reveals distinct patterns of tricarboxylic acid disorders in blood stasis syndrome associated with coronary heart disease[J]. Chin J Integr Med, 2016, 22(8):597-604.
[18] Xu X, Gao B, Guan Q, et al. Metabolomic profile for the early detection of coronary artery disease by using UPLC-QTOF/MS[J]. J Pharm Biomed Anal, 2016, 129:34-42.
[19] Hansson GK. Inflammation, atherosclerosis, and coronary artery disease[J]. N Engl J Med, 2005, 352(16):1685-1695.
[20] Nilsson J. Atherosclerotic plaque vulnerability in the statin era[J]. Eur Heart J, 2017, 38(21):1638-1644.
[21] Tomas L, Edsfeldt A, Mollet IG, et al. Altered metabolism distinguishes high-risk from stable carotid atherosclerotic plaques[J]. Eur Heart J, 2018, 39(24):2301-2310.
[22] Defilippis AP, Trainor PJ, Hill BG, et al. Identification of a plasma metabolomic signature of thrombotic myocardial infarction that is distinct from non-thrombotic myocardial infarction and stable coronary artery disease[J]. PLoS One, 2017, 12(4):e0175591.
[23] Wang X, Wang D, Wu J, et al. Metabolic characterization of myocardial infarction using GC-MS-Based tissue metabolomics[J]. Int Heart J, 2017, 58(3):441-446.
[24] Catapano A L, Reiner Z, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)[J]. Atherosclerosis, 2011, 217(1):3-46.
[25] Wang TJ. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction[J]. Circulation, 2011, 123(5):551-565.
[26] Yla-Herttuala S, Bentzon JF, Daemen M, et al. Stabilization of atherosclerotic plaques:an update[J]. Eur Heart J, 2013, 34(42):3251-3258.
[27] Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)[J]. Eur Heart J, 2012, 33(13):1635-1701.
[28] Kibos A, Guerchicoff A. Susceptibility genes for coronary heart disease and myocardial infarction[J]. Acute Card Care, 2011, 13(3):136-142.
[29] Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000[J]. Circulation, 2004, 109(9):1101-1107.
[30] Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation[J]. Circulation, 2007, 116(22):2563-2570.
[31] Yao W, Gao Y, Wan Z. Serum metabolomics profiling to identify biomarkers for unstable angina[J]. Biomed Res Int, 2017, 2017:7657306.
[32] Wang X, Wang D, Yu X, et al. Non-targeted metabolomics identified a common metabolic signature of lethal ventricular tachyarrhythmia (LVTA) in two rat models[J]. Mol Biosyst, 2016, 12(7):2213-2223.
[33] Lewis GD, Asnani A, Gerszten RE. Application of metabolomics to cardiovascular biomarker and pathway discovery[J]. J Am Coll Cardiol, 2008, 52(2):117-123.
[34] Wang Z, Tang WH, Buffa JA, et al. Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide[J]. Eur Heart J, 2014, 35(14):904-910.
[35] Zhang L, Wei TT, Li Y, et al. Functional metabolomics characterizes a key role for N-acetylneuraminic acid in coronary artery diseases[J]. Circulation, 2018, 137(13):1374-1390.
[36] Li Y, Zhang D, He Y, et al. Investigation of novel metabolites potentially involved in the pathogenesis of coronary heart disease using a UHPLC-QTOF/MS-based metabolomics approach[J]. Sci Rep, 2017, 7(1):15357.
[37] Li R, Li F, Feng Q, et al. An LC-MS based untargeted metabolomics study identified novel biomarkers for coronary heart disease[J]. Mol Biosyst, 2016, 12(11):3425-3434.
[38] Zhang XZ, Zheng SX, Hou YM. A non-targeted liquid chromatographic-mass spectrometric metabolomics approach for association with coronary artery disease:An identification of biomarkers for depiction of underlying biological mechanisms[J]. Med Sci Monit, 2017, 23:613-622.
[39] Huang L, Zhang L, Li T, et al. Human plasma metabolomics implicates modified 9-cis-retinoic acid in the phenotype of left main artery lesions in acute ST-segment elevated myocardial infarction[J]. Sci Rep, 2018, 8(1):12958.
[40] Cui S, Li K, Ang L, et al. Plasma phospholipids and sphingolipids identify stent restenosis after percutaneous coronary intervention[J]. JACC Cardiovasc Interv, 2017, 10(13):1307-1316.
[41] Feng Q, Liu Z, Zhong S, et al. Integrated metabolomics and metagenomics analysis of plasma and urine identified microbial metabolites associated with coronary heart disease[J]. Sci Rep, 2016, 6:22525.
[42] Saleem M, Herrmann N, Dinoff A, et al. A Lipidomics approach to assess the association between plasma sphingolipids and verbal memory performance in coronary artery disease patients undertaking cardiac rehabilitation:A C18:0 signature for cognitive response to exercise[J]. J Alzheimers Dis, 2017, 60(3):829-841.
[43] Hadj Ahmed S, Koubaa N, Kharroubi W, et al. Identification of long and very long chain fatty acids, plasmalogen-C16:0 and phytanic acid as new lipid biomarkers in Tunisian coronary artery disease patients[J]. Prostaglandins Other Lipid Mediat, 2017, 131:49-58.
[44] Fan Y, Li Y, Chen Y, et al. Comprehensive metabolomic characterization of coronary artery diseases[J]. J Am Coll Cardiol, 2016, 68(12):1281-1293.
[45] Stegemann C, Pechlaner R, Willeit P, et al. Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study[J]. Circulation, 2014, 129(18):1821-1831.
[46] Meikle PJ, Wong G, Tsorotes D, et al. Plasma lipidomic analysis of stable and unstable coronary artery disease[J]. Arterioscler Thromb Vasc Biol, 2011, 31(11):2723-2732.
[47] Park JY, Lee SH, Shin MJ, et al. Alteration in metabolic signature and lipid metabolism in patients with angina pectoris and myocardial infarction[J]. PLoS One, 2015, 10(8):e0135228.
[48] Paapstel K, Kals J, Eha J, et al. Inverse relations of serum phosphatidylcholines and lysophosphatidylcholines with vascular damage and heart rate in patients with atherosclerosis[J]. Nutr Metab Cardiovasc Dis, 2018, 28(1):44-52.
[49] Morrish NJ, Wang SL, Stevens LK, et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes[J]. Diabetologia, 2001, 44(Suppl 2):S14-21.
[50] Eckel RH, Kahn R, Robertson RM, et al. Preventing cardiovascular disease and diabetes:a call to action from the American Diabetes Association and the American Heart Association[J]. Circulation, 2006, 113(25):2943-2946.
[51] Omori K, Katakami N, Yamamoto Y, et al. Identification of metabolites associated with onset of CAD in diabetic patients using CE-MS analysis:A pilot study[J]. J Atheroscler Thromb, 2019, 26(3):233-245.
[52] Tannock LR, Kirk EA, King VL, et al. Glucosamine supplementation accelerates early but not late atherosclerosis in LDL receptor-deficient mice[J]. J Nutr, 2006, 136(11):2856-2861.
[53] Youm YH, Nguyen KY, Grant RW, et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease[J]. Nat Med, 2015, 21(3):263-269.
[54] Prass K, Royl G, Lindauer U, et al. Improved reperfusion and neuroprotection by creatine in a mouse model of stroke[J]. J Cereb Blood Flow Metab, 2007, 27(3):452-459.
[55] Lygate CA, Bohl S, Ten Hove M, et al. Moderate elevation of intracellular creatine by targeting the creatine transporter protects mice from acute myocardial infarction[J]. Cardiovasc Res, 2012, 96(3):466-475.
[56] Ryu HM, Kim YJ, Oh EJ, et al. Hypoxanthine induces cholesterol accumulation and incites atherosclerosis in apolipoprotein E-deficient mice and cells[J]. J Cell Mol Med, 2016, 20(11):2160-2172.
[57] Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction[J]. Circulation, 2012, 126(16):2020-2035.
[58] Yao H, Shi P, Zhang L, et al. Untargeted metabolic profiling reveals potential biomarkers in myocardial infarction and its application[J]. Mol Biosyst, 2010, 6(6):1061-170.
[59] Nam M, Jung Y, Ryu DH, et al. A metabolomics-driven approach reveals metabolic responses and mechanisms in the rat heart following myocardial infarction[J]. Int J Cardiol, 2017, 227:239-246.
[60] Davis SR, Quinlivan EP, Stacpoole PW, et al. Plasma glutathione and cystathionine concentrations are elevated but cysteine flux is unchanged by dietary vitamin B-6 restriction in young men and women[J]. J Nutr, 2006, 136(2):373-378.
[61] Gregory JF, 3rd, Park Y, Lamers Y, et al. Metabolomic analysis reveals extended metabolic consequences of marginal vitamin B-6 deficiency in healthy human subjects[J]. PLoS One, 2013, 8(6):e63544.
[62] Lima CP, Davis SR, Mackey AD, et al. Vitamin B-6 deficiency suppresses the hepatic transsulfuration pathway but increases glutathione concentration in rats fed AIN-76A or AIN-93G diets[J]. J Nutr, 2006, 136(8):2141-2147.
[63] Deratt BN, Ralat MA, Lysne V, et al. Metabolomic evaluation of the consequences of plasma cystathionine elevation in adults with stable angina pectoris[J]. J Nutr, 2017, 147(9):1658-1668.
[64] Nystoriak MA, Bhatnagar A. Cardiovascular effects and benefits of exercise[J]. Front Cardiovasc Med, 2018, 5:135.
[65] Kanikarla-Marie P, Jain SK. Hyperketonemia (acetoacetate) upregulates NADPH oxidase 4 and elevates oxidative stress, ICAM-1, and monocyte adhesivity in endothelial cells[J]. Cell Physiol Biochem, 2015, 35(1):364-373.
[66] Nomura A, Zhang M, Sakamoto T, et al. Anti-inflammatory activity of creatine supplementation in endothelial cells in vitro[J]. Br J Pharmacol, 2003, 139(4):715-720.
[67] Deidda M, Piras C, Cadeddu Dessalvi C, et al. Blood metabolomic fingerprint is distinct in healthy coronary and in stenosing or microvascular ischemic heart disease[J]. J Transl Med, 2017, 15(1):112.
[68] Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2015 update:a report from the American Heart Association[J]. Circulation, 2015, 131(4):e29-322.
[69] Hlatky MA, Shilane D, Chang TI, et al. Incremental prognostic information from kidney function in patients with new onset coronary heart disease[J]. Am Heart J, 2014, 167(1):86-92.
[70] Heather LC, Wang X, West JA, et al. A practical guide to metabolomic profiling as a discovery tool for human heart disease[J]. J Mol Cell Cardiol, 2013, 55:2-11.
[71] Zou HM, Zhang B, Xu XC, et al. Urinary metabolomic strategy to evaluate Compound Danshen Dripping Pills for myocardial ischaemia in rats[J]. J Pharm Biomed Anal, 2015, 112:98-105.
[72] Winder WW, Holmes BF, Rubink DS, et al. Activation of AMP-activated protein kinase increases mitochondrial en-zymes in skeletal muscle[J]. J Appl Physiol (1985), 2000, 88(6):2219-2226.
[73] Lo M, Wang YZ, Gout PW. The x(c)-cystine/glutamate antiporter:a potential target for therapy of cancer and other diseases[J]. J Cell Physiol, 2008, 215(3):593-602.
[74] Wernerman J, Hammarqvist F. Modulation of endogenous glutathione availability[J]. Curr Opin Clin Nutr Metab Care, 1999, 2(6):487-492.
[75] Mu F, Duan J, Bian H, et al. Metabonomic strategy for the evaluation of Chinese medicine Salvia miltiorrhiza and Dalbergia odorifera interfering with myocardial ischemia/reperfusion injury in rats[J]. Rejuvenation Res, 2017, 20(4):263- 277.
[76] Mu F, Duan J, Bian H, et al. Cardioprotective effects and mechanism of Radix Salviae miltiorrhizae and Lignum Dalbergiae odoriferae on rat myocardial ischemia/reperfusion injury[J]. Mol Med Rep, 2017, 16(2):1759-1770.
[77] Liu YT, Jia HM, Chang X, et al. Metabolic pathways involved in Xin-Ke-Shu protecting against myocardial infarction in rats using ultra high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry[J]. J Pharm Biomed Anal, 2014, 90:35-44.
[78] Liu YT, Peng JB, Jia HM, et al. UPLC-Q/TOF MS standardized Chinese formula Xin-Ke-Shu for the treatment of atherosclerosis in a rabbit model[J]. Phytomedicine, 2014, 21(11):1364-1372.
[79] Yang Y, Jia H, Yu M, et al. Chinese patent medicine Xin- Ke-Shu inhibits Ca2+ overload and dysfunction of fatty acid beta-oxidation in rats with myocardial infarction induced by LAD ligation[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2018, 1079:85-94.
[80] Jiang M, Wang Q, Chen J, et al. Comparative metabonomics of Wenxin Keli and Verapamil reveals differential roles of gluconeogenesis and fatty acid beta-oxidation in myocardial injury protection[J]. Sci Rep, 2017, 7(1):8739.
[81] Zheng GH, Xiong SQ, Chen HY, et al. Association of platelet- activating factor receptor gene rs5938(G/T) and rs313152(T/C) polymorphisms with coronary heart disease and blood stasis syndrome in a Chinese Han population[J]. Chin J Integr Med, 2017, 23(12):893-900.
[82] Tian Y, Yang ZF, Li Y, et al. Pharmacokinetic comparisons of hydroxysafflower yellow A in normal and blood stasis syndrome rats[J]. J Ethnopharmacol, 2010, 129(1):1-4.
[83] Tan J, Wang C, Zhu H, et al. Comprehensive metabolomics analysis of Xueshuan Xinmaining Tablet in blood stasis model rats using UPLC-Q/TOF-MS[J]. Molecules, 2018, 23(7):1650
[84] Li CY, Deng W, Liao XQ, et al. The effects and mechanism of ginsenoside Rg1 on myocardial remodeling in an animal model of chronic thromboembolic pulmonary hypertension[J]. Eur J Med Res, 2013, 18:16.
[85] Xia R, Zhao B, Wu Y, et al. Ginsenoside Rb1 preconditioning enhances eNOS expression and attenuates myocardial ischemia/reperfusion injury in diabetic rats[J]. J Biomed Biotechnol, 2011, 2011:767930.
[86] Ishibashi H, Mochidome T, Okai J, et al. Activation of potassium conductance by ophiopogonin-D in acutely dissociated rat paratracheal neurones[J]. Br J Pharmacol, 2001, 132(2):461-466.
[87] Wang YH, Qiu C, Wang DW, et al. Identification of multiple constituents in the traditional Chinese medicine formula Sheng-Mai San and rat plasma after oral administration by HPLC-DAD-MS/MS[J]. J Pharm Biomed Anal, 2011, 54(5):1110-1127.
[88] Jiang M, Kang L, Wang Y, et al. A metabonomic study of cardioprotection of ginsenosides, schizandrin, and ophiopogonin D against acute myocardial infarction in rats[J]. BMC Complement Altern Med, 2014, 14:350.
[89] Shimokawa H, Yasuda S. Myocardial ischemia:current concepts and future perspectives[J]. J Cardiol, 2008, 52(2):67-78.
[90] Le Page S, Prunier F. Remote ischemic conditioning:Current clinical perspectives[J]. J Cardiol, 2015, 66(2):91-96.
[91] Du Z, Shu Z, Lei W, et al. Integration of metabonomics and transcriptomics reveals the therapeutic effects and mechanisms of Baoyuan Decoction for myocardial ischemia[J]. Front Pharmacol, 2018, 9:514.
[92] Tang WH, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk[J]. N Engl J Med, 2013, 368(17):1575-1584.

Related Articles:
1. JIA Yan, ZHANG Zheng-Zheng, WEI Yu-Hai, Qin Xue-Mei, LI Zhen-Yu.Metabolomics coupled with similarity analysis advances the eluci-dation of the cold/hot properties of traditional Chinese medicines[J]. Chinese Journal of Natural Medicines, 2017,15(8): 631-640
2. YAN Shi-Kai, LIU Run-Hui, JIN Hui-Zi, LIU Xin-Ru, YE Ji, SHAN Lei, ZHANG Wei-Dong.“Omics” in pharmaceutical research:overview, applications, challenges, and future perspectives[J]. Chinese Journal of Natural Medicines, 2015,13(1): 3-21
3. WANG Xi-Jun, YAN Guang-Li, ZHANG Ai-Hua, SUN Hui, PIAO Cheng-Yu, LI Wei-Yun, SUN Chang, WU Xiu-Hong, LI Xing-Hua, CHEN Yun.Metabolomics and proteomics approaches to characterize and assess proteins of bear bile powder for hepatitis C virus[J]. Chinese Journal of Natural Medicines, 2013,11(6): 653-665